We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Incyte Corporation | NASDAQ:INCY | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.30 | -0.53% | 56.76 | 56.75 | 56.77 | 57.38 | 56.37 | 56.86 | 1,519,272 | 18:24:20 |
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.
See
Instruction 1(b).
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
OMB APPROVAL
OMB Number: 3235-0287 Estimated average burden hours per response... 0.5 |
|
|
|
1. Name and Address of Reporting Person
*
BAKER BROS. ADVISORS LP |
2. Issuer Name
and
Ticker or Trading Symbol
INCYTE CORP [ INCY ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__ X __ Director __ X __ 10% Owner _____ Officer (give title below) _____ Other (specify below) |
667 MADISON AVENUE, 21ST FLOOR |
3. Date of Earliest Transaction
(MM/DD/YYYY)
|
|
NEW YORK, NY 10065 |
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
___ Form filed by One Reporting Person _ X _ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |
||||||||||
1.Title of Security
(Instr. 3) |
2. Trans. Date | 2A. Deemed Execution Date, if any |
3. Trans. Code
(Instr. 8) |
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) |
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Stock | 58632 (1) | D | ||||||||
Common Stock | 61049 (2) | D | ||||||||
Common Stock | 33410 | I | See Footnote (3) | |||||||
Common Stock | 4/27/2017 | M | 20000 | A | $7.26 | 4374099 | I | See Footnote (4) (5) (9) (10) (14) | ||
Common Stock | 4/27/2017 | M | 20000 | A | $7.26 | 29161795 | I | See Footnote (5) (6) (9) (11) (12) (14) | ||
Common Stock | 4/27/2017 | M | 20000 | A | $7.26 | 787237 | I | See Footnote (5) (7) (9) (12) (13) (14) |
Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) |
|||||||||||||||
1. Title of Derivate Security
(Instr. 3) |
2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any |
4. Trans. Code
(Instr. 8) |
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) |
6. Date Exercisable and Expiration Date |
7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) |
8. Price of Derivative Security
(Instr. 5) |
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||||||
Non-Qualified Stock Options (right | $7.26 | 4/27/2017 | M | 20000 | 5/22/2008 | 5/21/2017 | Common Stock | 20000 | $0 (8) | 0 | I | See Footnotes (4) (9) | |||
Non-Qualified Stock Options (right | $7.26 | 4/27/2017 | M | 20000 | 5/22/2008 | 5/21/2017 | Common Stock | 20000 | $0 (8) | 0 | I | See Footnotes (6) (9) | |||
Non-Qualified Stock Options (right | $7.26 | 4/27/2017 | M | 20000 | 5/22/2008 | 5/21/2017 | Common Stock | 20000 | $0 (8) | 0 | I | See Footnotes (7) (9) |
Remarks:
Julian C. Baker is a director of Incyte Corporation (the "Issuer"). By virtue of his representation on the Board of Directors of the Issuer, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the reporting persons are deemed directors by deputization of the Issuer. |
Reporting Owners
|
|||||
Reporting Owner Name / Address |
|
||||
Director | 10% Owner | Officer | Other | ||
BAKER BROS. ADVISORS LP
667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY 10065 |
X | X |
|
|
|
14159, L.P.
667 MADISION AVENUE, 21ST FLOOR NEW YORK, NY 10065 |
X | X |
|
|
|
667, L.P.
667 MADISION AVENUE, 21ST FLOOR NEW YORK, NY 10065 |
X | X |
|
|
|
BAKER FELIX
667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY 10065 |
X | X |
|
|
|
BAKER JULIAN
667 MADISON AVENUE, 21ST FLOOR NEW YORK, NY 10065 |
X | X |
|
|
|
Baker Bros. Advisors (GP) LLC
667 MADISION AVENUE, 21ST FLOOR NEW YORK, NY New York |
X | X |
|
|
|
Baker Brothers Life Sciences LP
667 MADISION AVENUE, 21ST FLOOR NEW YORK, NY 10065 |
X | X |
|
|
Signatures
|
||
By: Baker Bros. Advisors LP, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing | 4/28/2017 | |
** Signature of Reporting Person |
Date
|
|
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 14159, L.P., pursuant to authority granted by 14159 Capital, L.P., GP to 14159, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing | 4/28/2017 | |
** Signature of Reporting Person |
Date
|
|
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to 667, L.P., pursuant to authority granted by Baker Biotech Capital, L.P., GP to 667, L.P. Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing | 4/28/2017 | |
** Signature of Reporting Person |
Date
|
|
/s/ Felix J. Baker | 4/28/2017 | |
** Signature of Reporting Person |
Date
|
|
/s/ Julian C. Baker | 4/28/2017 | |
** Signature of Reporting Person |
Date
|
|
By: Baker Bros. Advisors (GP) LLC, Name: Scott L. Lessing, Title: President /s/ Scott L. Lessing | 4/28/2017 | |
** Signature of Reporting Person |
Date
|
|
Baker Bros. Advisors LP, Mgmt. Co. and Inv. Adviser to BAKER BROTHERS LIFE SCIENCES, L.P., pursuant to authority granted by Baker Brothers Life Sciences Capital, L.P., GP to Baker Brothers Life Sciences, L.P Name: Scott L. Lessing, Title: President /s/ | 4/28/2017 | |
** Signature of Reporting Person |
Date
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 4(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Incyte Chart |
1 Month Incyte Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions